NCT01278095View on ClinicalTrials.gov

Oral Bioavailability of GLPG0555 in Different Solid Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2011

Study Completion Date

March 31, 2011

Conditions
Healthy
Interventions
DRUG

GLPG0555 solid dispersion

solid dispersion capsules, 50 mg, single dose

DRUG

GLPG0555 nanosuspension

Nanosuspension, 50 mg, single dose

Trial Locations (1)

2060

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY